stars 1 stars 2 stars 3

ViVac is a biotechnology company reprogramming immunity through synthetic RNA and precision Lipid Nanoparticle (LNP) delivery. Our platform recreates the immune activation of viral infections—without the risks—to drive the next generation of cancer immunotherapies. Unlike conventional treatments that stimulate only parts of the immune system, ViVac’s synthetic RNA encodes a complete yet replication-limited viral blueprint. This enables full activation of cellular and antibody responses while maintaining intrinsic safety. Led by pioneers in synthetic biology and LNP engineering, and backed by leading life-science investors, ViVac is advancing a universal, one-cycle RNA platform designed to turn tumors into immune activation sites and target cancer system-wide. Our initial proof-of-concept using a poliovirus backbone has demonstrated strong in-vitro results and validated tumor-targeted delivery in vivo.

Website http://www.vivacpharma.com
Employees 4 (4 on RocketReach)
Founded 2023
Industry Biotechnology Research

ViVac Pharma Questions

Keren Leshem is the Chief Executive Officer and Board Director of ViVac Pharma.

4 people are employed at ViVac Pharma.

Top ViVac Pharma Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users